Data / Drug companies / Endoglycosidase
Endoglycosidase drugs: 11 drugs from 12 companies in the FDA NDC directory
Endoglycosidase is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 27 products in this class from 12 companies, covering 11 drugs by generic name. The main marketing category is biologics (BLA), and the newest product started marketing on February 13, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 12Companies
- 27Products
- 11Drugs by generic name
Drugs in the Endoglycosidase class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Hyaluronidase | 3 | 3 |
| Amivantamab and hyaluronidase-lpuj (human recombinant) | 4 | 1 |
| Efgartigimod alfa and hyaluronidase (human recombinant) | 2 | 1 |
| Nivolumab and hyaluronidase-nvhy | 2 | 1 |
| Pembrolizumab and berahyaluronidase alfa-pmph | 2 | 1 |
| Pertuzumab, trastuzumab, and hyaluronidase-zzxf | 2 | 1 |
| Rituximab and hyaluronidase | 2 | 1 |
| Atezolizumab and hyaluronidase-tqjs | 1 | 1 |
| Daratumumab and hyaluronidase-fihj (human recombinant) | 1 | 1 |
| Ocrelizumab and hyaluronidase | 1 | 1 |
| Trastuzumab and hyaluronidase-oysk | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Genentech, Inc. | 7 | injection, solution; injection | Biologics (BLA) | September 13, 2024 |
| Janssen Biotech, Inc. | 5 | injection | Biologics (BLA) | February 13, 2026 |
| Deseret Biologicals, Inc. | 3 | liquid | Unapproved homeopathic products | December 13, 2024 |
| Argenx US | 2 | injection, solution | Biologics (BLA) | April 10, 2025 |
| E.r. Squibb & Sons, L.L.C. | 2 | injection, solution | Biologics (BLA) | January 2, 2025 |
| Merck Sharp & Dohme LLC | 2 | injection, solution | Biologics (BLA) | September 19, 2025 |
| Amphastar Pharmaceuticals, Inc. | 1 | injection | Biologics (BLA) | October 26, 2004 |
| Antares Pharma, Inc. | 1 | injection, solution | Biologics (BLA) | December 2, 2005 |
| BioActive Nutritional, Inc. | 1 | liquid | Unapproved homeopathic products | June 15, 2022 |
| Energique, Inc. | 1 | liquid | Unapproved homeopathic products | December 28, 2022 |
| Guna Spa | 1 | solution/ drops | Unapproved homeopathic products | May 27, 2010 |
| HF Acquisition Co LLC, DBA HealthFirst | 1 | injection, solution | Biologics (BLA) | June 4, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 14 | 51.9% |
| Injection | 7 | 25.9% |
| Liquid | 5 | 18.5% |
| Solution/ drops | 1 | 3.7% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.